Drug intelligence / Profile preview

C-SLN + antisense oligonucleotide targeting IGFL2-AS1

Development stage: Preclinical
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

C-SLN + antisense oligonucleotide targeting IGFL2-AS1 is an experimental nanomedicine developed for the treatment of sunitinib-resistant clear cell renal cell carcinoma (ccRCC). The therapeutic consists of an antisense oligonucleotide (ASO) encapsulated within chitosan-modified solid lipid nanoparticles (C-SLN) for targeted delivery. The ASO is designed to silence the long non-coding RNA (lncRNA) IGFL2-AS1, which is significantly upregulated in resistant RCC cells. IGFL2-AS1 normally promotes sunitinib resistance by binding to the RNA-binding protein hnRNPC, which prevents the suppression of TP53INP2, leading to increased autophagy and cell survival. By degrading IGFL2-AS1, the C-SLN/ASO complex suppresses this autophagic pathway and restores the sensitivity of cancer cells to sunitinib. Preclinical evidence in patient-derived xenograft models has shown that intravenous administration of this complex can successfully reverse drug resistance.

Other names: chitosan-solid lipid nanoparticles containing antisense oligonucleotide-IGFL2-AS1C-SLN + ASO-IGFL2-AS1

Targets

IGFL2-AS1 (IGFL2 antisense RNA 1)

Beyond the preview

Go deeper on C-SLN + antisense oligonucleotide targeting IGFL2-AS1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-SLN + antisense oligonucleotide targeting IGFL2-AS1.

Explore the full profile